DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Brigatinibis the generic ingredient in one branded drug marketed by Ariad and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Brigatinib has sixty-two patent family members in thirty-three countries.
One supplier is listed for this compound.
Pharmacology for brigatinib
|Drug Class||Kinase Inhibitor |
|Mechanism of Action||Tyrosine Kinase Inhibitors |
Cytochrome P450 3A Inducers
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Ariad||ALUNBRIG||brigatinib||TABLET;ORAL||208772-001||Apr 28, 2017||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|Ariad||ALUNBRIG||brigatinib||TABLET;ORAL||208772-001||Apr 28, 2017||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Ariad||ALUNBRIG||brigatinib||TABLET;ORAL||208772-002||Apr 28, 2017||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Ariad||ALUNBRIG||brigatinib||TABLET;ORAL||208772-003||Oct 2, 2017||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2300013||122019000046||Germany||Start Trial||PRODUCT NAME: BRIGATINIB, ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1264 20181122|
|2300013||LUC00120||Luxembourg||Start Trial||PRODUCT NAME: BRIGATINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1264 20181126|
|2300013||132019000000069||Italy||Start Trial||PRODUCT NAME: BRIGATINIB, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ALUNBRIG); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1264, 20181126|
|2300013||CA 2019 00028||Denmark||Start Trial||PRODUCT NAME: BRIGATINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; REG. NO/DATE: EU/1/18/1264 20181126|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.